Tumor Protein Affects Cisplatin Outcome in Lung Cancer

Patients with completely resected non-small-cell lung cancer who are negative for ERCC1 get better results

WEDNESDAY, Sept. 6 (HealthDay News) -- Patients with completely resected non-small-cell lung cancer who have tumors that do not express the excision repair cross-complementation group 1 (ERCC1) protein have better outcomes from treatment with cisplatin-based adjuvant chemotherapy than those with ERCC1-positive tumors, according to a report published in the Sept. 7 issue of the New England Journal of Medicine.

Jean-Charles Soria, M.D., Ph.D., of the Institut Gustave Roussy in Villejuif, France, and colleagues analyzed 761 tumors, and found ERCC1 expression in 335 tumors (44 percent) and no expression in the remainder.

In patients with ERCC1-negative tumors, cisplatin-based adjuvant therapy decreased death by 35 percent compared with expected observations, while having no impact on those with ERCC1-positive tumors. Among those who did not receive any adjuvant therapy, patients with ERCC1-positive tumors survived 34 percent longer than their ERCC1-negative counterparts.

"Our results suggest that determination of ERCC1 expression in non-small-cell lung cancer cells before chemotherapy can make a contribution as an independent predictor of the effect of adjuvant therapy," the authors conclude. "Since the type of immunohistochemical analysis we used can be applied in almost every pathology laboratory, our findings could be widely applicable if confirmed by independent studies."

Full Text (subscription or payment may be required)

Physician's Briefing